BACKGROUND: Bilateral neck treatment in oropharyngeal squamous cell carcinoma (OPSCC) is controversial. This study determined the rate of bilateral neck metastases in OPSCC and formulated a neck treatment algorithrm for OPSCC. METHODS: In all, 212 consecutive patients with OPSCC underwent ipsilateral level I-V and contralateral I-III or I-V neck dissections. Pathology results were used to identify factors predicting bilateral neck metastases. RESULTS: A total of 171 patients (81%) had ipsilateral and 41 patients (24%) bilateral neck metastases. Multivariate logistic regression found cT4 and ≥cN2a significantly associated with contralateral neck metastases (p < .05). However, tumor site was not predictive (p > .05). High-risk pathology features predicted contralateral neck disease (p < .05). cN0 and cN1 necks were unlikely to harbor disease in level V (<5%). Both 2- and 5-year contralateral neck recurrence rates were 1% and 2%. CONCLUSIONS: Bilateral neck disease in OPSCC is more common than once thought. Patients with OPSCC with cT4 or cN2a+ would benefit from bilateral neck treatment. Posttreatment high-risk features should guide treatment escalation.
BACKGROUND: Bilateral neck treatment in oropharyngeal squamous cell carcinoma (OPSCC) is controversial. This study determined the rate of bilateral neck metastases in OPSCC and formulated a neck treatment algorithrm for OPSCC. METHODS: In all, 212 consecutive patients with OPSCC underwent ipsilateral level I-V and contralateral I-III or I-V neck dissections. Pathology results were used to identify factors predicting bilateral neck metastases. RESULTS: A total of 171 patients (81%) had ipsilateral and 41 patients (24%) bilateral neck metastases. Multivariate logistic regression found cT4 and ≥cN2a significantly associated with contralateral neck metastases (p < .05). However, tumor site was not predictive (p > .05). High-risk pathology features predicted contralateral neck disease (p < .05). cN0 and cN1 necks were unlikely to harbor disease in level V (<5%). Both 2- and 5-year contralateral neck recurrence rates were 1% and 2%. CONCLUSIONS: Bilateral neck disease in OPSCC is more common than once thought. Patients with OPSCC with cT4 or cN2a+ would benefit from bilateral neck treatment. Posttreatment high-risk features should guide treatment escalation.
Authors: Karl Christoph Sproll; Sabina Leydag; Henrik Holtmann; Lara K Schorn; Joel Aissa; Patric Kröpil; Wolfgang Kaisers; Csaba Tóth; Jörg Handschel; Julian Lommen Journal: J Cancer Res Clin Oncol Date: 2021-02-01 Impact factor: 4.553
Authors: Aisling S Last; Patrik Pipkorn; Stephanie Chen; Dorina Kallogjeri; Joseph Zenga; Jason T Rich; Randal Paniello; Jose Zevallos; Rebecca Chernock; Douglas Adkins; Peter Oppelt; Hiram Gay; Mackenzie Daly; Wade Thorstad; Ryan S Jackson Journal: JAMA Otolaryngol Head Neck Surg Date: 2020-01-01 Impact factor: 6.223
Authors: Shlomo A Koyfman; Nofisat Ismaila; Doug Crook; Anil D'Cruz; Cristina P Rodriguez; David J Sher; Damian Silbermins; Erich M Sturgis; Terance T Tsue; Jared Weiss; Sue S Yom; F Christopher Holsinger Journal: J Clin Oncol Date: 2019-02-27 Impact factor: 44.544
Authors: Han Zhang; Hadi Seikaly; Jonathan T Abele; Dean T Jeffery; Jeffrey R Harris; Daniel A O'Connell Journal: J Otolaryngol Head Neck Surg Date: 2014-10-13